Importance of Timing and Impact of Extensive Revascularization on Long-Term Survival in Cardiogenic Shock: Insights From European Multi-Center Studies
Presented by Giuseppe Tarantini, MD, PhD
Giuseppe Tarantini, MD, PhD, FESC discusses insights from European multi-center studies regarding the timing and impact of extensive revascularization on long-term survival in cardiogenic shock.
With regard to timing, Dr. Tarantini discusses the ideal window of opportunity for percutaneous ventricular assist device (pVAD) insertion as cardiogenic shock progresses from the compensated stage through the progressive stage to the irreversible stage, noting that the ideal case entails Impella® support before the onset of cardiogenic shock to prevent it from occurring. He emphasizes “DTU” is more important than “DTB.” In other words, restoring patients’ physiology/circulation is more important than immediate opening of an occluded vessel and longer symptom to support (S2S) time is associated with increased mortality. Dr. Tarantini also presents data, including data from the Registry of Patients Treated with IMPella Mechanical Circulatory Support Device in Italy (R-IMP-IT), demonstrating a clear survival advantage at 1 year with more extensive revascularization with Impella support in the setting of cardiogenic shock.
Dr. Tarantini is professor and director of interventional cardiology at the University of Padua in Italy and GISE president.
This video is part of a series: Achieving >70% AMI-CS Survival: Best Practices From Around the World
- Achieving >70% AMI-CS Survival: Insight From National Cardiogenic Shock Initiative (William O'Neill, MD)
- Efficacy and Safety of ALL Impella Use in Japanese Patients With Drug-Resistant Acute HF: Insight From Japan J-PVAD Study (Junya Ako, MD)
- Importance of Timing and Impact of Extensive Revascularization on Long-Term Survival in Cardiogenic Shock: Insights From European Multi-Center Studies (Giuseppe Tarantini, MD, PhD) [current page]
- Closing Summation, RECOVER III, and Intro to RECOVER IV (William O'Neill, MD)
To learn more about the Impella® platform of heart pumps, including important risk and safety information associated with the use of the devices, please visit: abiomed.com/important-safety-information